Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04675242 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
A Phase 2 study, sponsored by Nicox Ophthalmics.
- Completed
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
NCT04675242 is a Phase 2 study that has completed, run by Nicox Ophthalmics. The registered enrollment target is 224 participants.
The verdict
NCT04675242, a Phase 2 study, has completed, sponsored by Nicox Ophthalmics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of blepharitis.
Interventions
- DRUG Placebo
- DRUG NCX 4251
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04675242
The ClinicalTrials.gov registry entry for NCT04675242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nicox Ophthalmics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04675242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04675242 about?
NCT04675242 is a clinical study titled "Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis". This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of blepharitis.
What is the current status of trial NCT04675242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2020-12-14. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04675242?
The interventions under investigation include: Placebo (DRUG), NCX 4251 (DRUG).
Who is sponsoring clinical trial NCT04675242?
This trial is sponsored by Nicox Ophthalmics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.